Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John A Davis

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
Leukemia|September 23, 2022
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1Warren Fiskus, Naval Daver, Steffen Boettcher, et al.
Blood Cancer Journal|January 12, 2022
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)Warren Fiskus, Steffen Boettcher, Naval Daver, et al.
Leukemia|December 19, 2025
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AMLChristine E Birdwell, Warren Fiskus, Christopher P Mill, et al.
Blood|October 3, 2021
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
Leukemia|March 12, 2026
Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AMLChristine E Birdwell, Warren Fiskus, Christopher P Mill, et al.
Leukemia|December 12, 2023
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpressionChristine E Birdwell, Warren Fiskus, Tapan M Kadia, et al.
Blood Cancer Journal|April 13, 2023
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1Warren Fiskus, Christopher P Mill, Christine Birdwell, et al.
Annals of Global Health|January 12, 2026
Pathways to Clinical Training Opportunities for International Medical Students and IMGs: The California ExperienceMargaret Akey, Brian Groves, James C Hudspeth, et al.
BMC Medical Education|May 1, 2024
Sexual and gender minority content in undergraduate medical education in the United States and Canada: current state and changes since 2011Carl G Streed, Amy Michals, Emily Quinn, et al.
Leukemia|March 3, 2021
BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphomaWarren Fiskus, Christopher P Mill, Dimuthu Perera, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
Leukemia|September 23, 2022
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1Warren Fiskus, Naval Daver, Steffen Boettcher, et al.
Blood Cancer Journal|January 12, 2022
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)Warren Fiskus, Steffen Boettcher, Naval Daver, et al.
Leukemia|December 19, 2025
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AMLChristine E Birdwell, Warren Fiskus, Christopher P Mill, et al.
Blood|October 3, 2021
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
Leukemia|March 12, 2026
Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AMLChristine E Birdwell, Warren Fiskus, Christopher P Mill, et al.
Leukemia|December 12, 2023
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpressionChristine E Birdwell, Warren Fiskus, Tapan M Kadia, et al.
Blood Cancer Journal|April 13, 2023
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1Warren Fiskus, Christopher P Mill, Christine Birdwell, et al.
Annals of Global Health|January 12, 2026
Pathways to Clinical Training Opportunities for International Medical Students and IMGs: The California ExperienceMargaret Akey, Brian Groves, James C Hudspeth, et al.
BMC Medical Education|May 1, 2024
Sexual and gender minority content in undergraduate medical education in the United States and Canada: current state and changes since 2011Carl G Streed, Amy Michals, Emily Quinn, et al.
Leukemia|March 3, 2021
BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphomaWarren Fiskus, Christopher P Mill, Dimuthu Perera, et al.
Pageof 9